Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease: An International, Multicenter, Epidemiological Protocol

NCT02416661 is registered in ClinicalTrials.gov with CENTOGENE GmbH Rostock as lead sponsor.

NCT NCT02416661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02416661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease: An International, Multicenter, Epidemiological Protocol
Lead sponsor
CENTOGENE GmbH Rostock
Phase
Observational
Overall status
Completed
Start date
August 27, 2018
Completion date
January 15, 2021
Enrollment
299 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease, lysosomal storage diseases, sphingolipidoses